ArticleBreast cancer (Tokyo, Japan)2025
Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).
Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registries.ESMO real world data and digital oncology · 2026Article
- Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).Breast cancer (Tokyo, Japan) · 2026Article
- Preliminary Insights into Quality of Life and Dietary Intake in Patients with Breast Cancer on Adjuvant Endocrine Therapy.Cancers · 2025Article
- CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPatients with early recurrence of hormone receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer have a poor prognosis. We aimed to identify clinical and pathological risk factors for recurrence within three years after surgery of HR+/HER2- breast cancer.
methodsWe retrospectively reviewed clinical data of patients with stage II-III HR+/HER2- breast cancer who received adjuvant endocrine therapy from January 1, 2012 to January 1, 2017 at five institutions. Using univariable and multivariable analyses, we determined risk factors for invasive disease-free survival (IDFS). A nomogram was generated using variables from the multivariable analysis to predict 3-year IDFS rate.
resultsA total of 2732 patients were analyzed, with a median follow-up of 7.1 years. The 3-year IDFS rate was 92.1%. Multivariable analysis for IDFS revealed significant risk factors: age (40-69 vs. 20-39 years: HR 0.69, p = 0.011), nuclear grade (Grade 2 vs. Grade 1: HR 1.66, p < 0.001; Grade 3 vs. Grade 1: HR 1.64, p < 0.001), vascular invasion (Yes vs. No: HR 1.36, p = 0.027), pathological invasive tumor size (2-5 cm vs. < 2 cm: HR 1.75, p < 0.001; ≥ 5 cm vs. < 2 cm: HR 2.07, p < 0.001), number of positive lymph nodes (≥ 4 vs.0: HR 1.70, p < 0.001), and neoadjuvant chemotherapy (NAC) (Yes vs. No: HR 2.41, p < 0.001). The nomogram's concordance index was 0.68.
conclusionYounger age, nuclear grade, vascular invasion, tumor size and number of lymph node metastases were identified as independent risk factors for early recurrence. Patients whose physicians chose NAC had worse survival than those who did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.